potassium phosphate, monobasic 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4480 7778-77-0

Description:

MoleculeDescription

Synonyms:

  • potassium phosphate, monobasic
  • potassium phosphate monobasic
  • monobasic potassium phosphate
  • Molecular weight: 136.08
  • Formula: H2KO4P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 80.59
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 2, 1979 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 40.51 33.44 18 1408 46426 90580595
Immune effector cell-associated neurotoxicity syndrome 37.15 33.44 10 1416 5758 90621263
Hypophosphataemia 35.55 33.44 12 1414 14842 90612179
Cytokine release syndrome 34.94 33.44 14 1412 27959 90599062
Myocardial reperfusion injury 33.51 33.44 5 1421 139 90626882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 70.46 27.85 28 1352 26722 42593233
Febrile neutropenia 52.15 27.85 45 1335 185658 42434297
Cytokine release syndrome 50.86 27.85 26 1354 44501 42575454
Respiratory failure 48.51 27.85 37 1343 128095 42491860

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 85.37 24.44 40 2846 70266 110516147
Febrile neutropenia 75.80 24.44 64 2822 316703 110269710
Toxic epidermal necrolysis 55.92 24.44 28 2858 56699 110529714
Respiratory failure 50.37 24.44 43 2843 215289 110371124
Immune effector cell-associated neurotoxicity syndrome 44.03 24.44 16 2870 14766 110571647
Hypophosphataemia 34.52 24.44 17 2869 33165 110553248
Nephrocalcinosis 33.10 24.44 8 2878 1806 110584607
Myocardial reperfusion injury 30.94 24.44 5 2881 140 110586273
Encephalopathy 29.38 24.44 21 2865 81034 110505379
Septic shock 26.15 24.44 26 2860 157502 110428911

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:33287 fertilizers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia off-label use 4996001
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Hypocalcemia contraindication 5291005
Hyperkalemia contraindication 14140009
Cirrhosis of liver contraindication 19943007 DOID:5082
Hyperphosphatemia contraindication 20165001 DOID:0050459
Hypernatremia contraindication 39355002
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Oliguria contraindication 83128009
Hyporeninemic hypoaldosteronism contraindication 236464008
Edema contraindication 267038008
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) POTASSIUM PHOSPHATES CMP DEV LLC N212121 Sept. 19, 2019 DISCN SOLUTION INTRAVENOUS 10632150 April 19, 2039 POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Intestinal alkaline phosphatase Enzyme IC50 5.62 CHEMBL

External reference:

IDSource
D02050 KEGG_DRUG
4018695 VUID
N0000147004 NUI
4018695 VANDF
CHEMBL1200925 ChEMBL_ID
DB09413 DRUGBANK_ID
55019 RXNORM
5131 MMSL
5323 MMSL
NOCODE MMSL
d01424 MMSL
001189 NDDF
002335 NDDF
61244006 SNOMEDCT_US
C0138038 UMLSCUI
CHEBI:63036 CHEBI
516951 PUBCHEM_CID
4J9FJ0HL51 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.00 g INTRAVENOUS NDA 24 sections
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.00 g INTRAVENOUS NDA 24 sections
Dextrose and Electrolyte No. 48 HUMAN PRESCRIPTION DRUG LABEL 6 0338-0143 INJECTION 20 mg INTRAVENOUS NDA 19 sections
Dextrose and Electrolyte No. 48 HUMAN PRESCRIPTION DRUG LABEL 6 0338-0143 INJECTION 20 mg INTRAVENOUS NDA 19 sections
TIS-U-SOL HUMAN PRESCRIPTION DRUG LABEL 5 0338-0190 IRRIGANT 6.25 mg IRRIGATION NDA 5 sections
TIS-U-SOL HUMAN PRESCRIPTION DRUG LABEL 5 0338-0190 IRRIGANT 6.25 mg IRRIGATION NDA 5 sections
TIS-U-SOL HUMAN PRESCRIPTION DRUG LABEL 5 0338-0190 IRRIGANT 6.25 mg IRRIGATION NDA 5 sections
TIS-U-SOL HUMAN PRESCRIPTION DRUG LABEL 5 0338-0190 IRRIGANT 6.25 mg IRRIGATION NDA 5 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0409-0032 INJECTION, SOLUTION, CONCENTRATE 224 mg INTRAVENOUS ANDA 22 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0409-0032 INJECTION, SOLUTION, CONCENTRATE 224 mg INTRAVENOUS ANDA 22 sections
K Phos Original HUMAN PRESCRIPTION DRUG LABEL 1 0486-1111 TABLET, SOLUBLE 500 mg ORAL unapproved drug other 18 sections
K Phos Original HUMAN PRESCRIPTION DRUG LABEL 1 0486-1111 TABLET, SOLUBLE 500 mg ORAL unapproved drug other 18 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 155 mg ORAL unapproved drug other 19 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 155 mg ORAL unapproved drug other 19 sections
K-Phos No. 2 HUMAN PRESCRIPTION DRUG LABEL 2 0486-1134 TABLET, COATED 305 mg ORAL unapproved drug other 18 sections
K-Phos No. 2 HUMAN PRESCRIPTION DRUG LABEL 2 0486-1134 TABLET, COATED 305 mg ORAL unapproved drug other 18 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2051 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2051 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2102 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2102 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2505 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Potassium Phosphates HUMAN PRESCRIPTION DRUG LABEL 2 0517-2505 INJECTION, SOLUTION 224 mg INTRAVENOUS ANDA 20 sections
Ionosol MB and Dextrose HUMAN PRESCRIPTION DRUG LABEL 6 0990-7372 INJECTION, SOLUTION 15 mg INTRAVENOUS NDA 15 sections
Ionosol MB and Dextrose HUMAN PRESCRIPTION DRUG LABEL 6 0990-7372 INJECTION, SOLUTION 15 mg INTRAVENOUS NDA 15 sections
Ionosol MB and Dextrose HUMAN PRESCRIPTION DRUG LABEL 6 0990-7372 INJECTION, SOLUTION 15 mg INTRAVENOUS NDA 15 sections
Ionosol MB and Dextrose HUMAN PRESCRIPTION DRUG LABEL 6 0990-7372 INJECTION, SOLUTION 15 mg INTRAVENOUS NDA 15 sections
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Human Prescription Drug Label 3 64980-104 TABLET 155 mg ORAL UNAPPROVED DRUG OTHER 19 sections
PHOSPHA 250 NEUTRAL Human Prescription Drug Label 3 64980-729 TABLET 155 mg ORAL UNAPPROVED DRUG OTHER 19 sections
POTASSIUM PHOSPHATES Human Prescription Drug Label 2 65145-194 INJECTION, SOLUTION, CONCENTRATE 224 mg INTRAVENOUS ANDA 21 sections
POTASSIUM PHOSPHATES Human Prescription Drug Label 2 65145-194 INJECTION, SOLUTION, CONCENTRATE 224 mg INTRAVENOUS ANDA 21 sections